

A. Originalarbeiten (peer review)

---

1. Considerable loss of information on skin cancer occurrence and non-adherence to clinical practice guideline in renal transplant recipients.  
Leinweber N, Dziunycz PJ, French LE, Wüthrich R, **Serra AL**, Hofbauer GF.  
J Eur Acad Dermatol Venereol. 2016 Feb 17.  
*IF 2.826*
2. EFSUMB statement on medical student education in ultrasound.  
Cantisani V, Dietrich CF, Badea R, Dudea S, Prosch H, Cerezo E, Nuernberg D, **Serra AL**, Sidhu PS, Radzina M, Piscaglia F, Bachmann Nielsen M, Calliada F, Gilja OH.  
Ultraschall Med. 2016 Feb;37(1):100-102. Epub 2016 Feb 12.  
*IF 4.645*
3. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).  
Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ et al.  
Autophagy. 2016 Jan 2;12(1):1-222.  
*IF 11.753*
4. Exposure to moxifloxacin and cytomegalovirus replication is associated with skin squamous cell carcinoma development in lung transplant recipients.  
Gerber SR, Seifert B, Inci I, **Serra AL**, Kohler M, Benden C, Hofbauer GF, Schuurmans MM.  
J Eur Acad Dermatol Venereol. 2015 Dec;29(12):2451-7.  
*IF 2.826*
5. Sclerostin quo vadis? - is this a useful long-term mortality parameter in prevalent hemodialysis patients?  
Nowak A, Artunc F, **Serra AL**, Pollock E, Krayenbühl PA, Müller C, Friedrich B.  
Kidney Blood Press Res. 2015;40(3):266-76.  
*IF 1.596*
6. Urinary biomarkers at early ADPKD disease stage.  
Petzold K, Poster D, Krauer F, Spanaus K, Andreisek G, Nguyen-Kim TD, Pavik I, Ho TA, **Serra AL**, Rotar L.  
PLoS One. 2015 Apr 13;10(4).  
*IF 3.730*
7. Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides.  
Schanstra JP, Zürbig P, Alkhalaf A, Argiles A, Bakker SJ, Beige J, Bilo HJ, Chatzikyrkou C, Dakna M, Dawson J, Delles C, Haller H, Haubitz M, Husi H, Jankowski J, Jerums G, Kleefstra N, Kuznetsova T, Maahs DM, Menne J, Mullen W, Ortiz A, Persson F, Rossing P, Ruggenenti P, Rychlik I, **Serra AL**, Siwy J, Snell-Bergeon J, Spasovski G, Staessen JA, Vlahou A, Mischak H, Vanholder R.  
J Am Soc Nephrol. 2015 Jan 14. pii: ASN.2014050423  
*IF 9.46*
8. Impaired expression of key molecules of ammoniogenesis underlies renal acidosis in a rat model of chronic kidney disease.  
Bürki R, Mohebbi N, Bettoni C, Wang X, **Serra AL**, Wagner CA.  
Nephrol Dial Transplant. 2015 May;30(5):770-81  
*IF 3.371*
9. Spectrophotometric intracutaneous analysis: an investigation on photodamaged skin of immunocompromised patients.  
Stimpfle DW, **Serra AL**, Wüthrich RP, French LE, Braun RP, Hofbauer GF.  
J Eur Acad Dermatol Venereol. 2014 Oct 13. doi: 10.1111/jdv.12771.  
*IF 2.69*
10. Prognostic value and link to atrial fibrillation of soluble klotho and FGF23 in hemodialysis patients.  
Nowak A, Friedrich B, Artunc F, **Serra AL**, Bredthardt T, Twerenbold R, Peter M, Mueller C.  
PLoS One. 2014, 2014 Jul 3;9(7):e100688. doi:

IF 3.730

11. Building a network of ADPKD Reference Centers across Europe: The EuroCYST Initiative. Katja Petzold, Ron T Gansevoort, Albert CM Ong, Olivier Devuyst, Laura Rotar, Kai-Uwe Eckardt, Anna Köttgen, Yves Pirson, Giuseppe Remuzzi, Richard Sandford, Vladimir Tesar, Süleyman Tevfik Ecder, Dominique Chaveau, Roser Torra, Klemens Budde, Rudolf P Wüthrich, Yannick Le Meur, **Serra AL**.  
Nephrol Dial Transplant. 2014, 29 (4):26-32

IF 3.371

12. Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. Siwy J, Schanstra JP, Argiles A, Bakker SJ, Beige J, Boucek P, Brand K, Delles C, Duranton F, Fernandez-Fernandez B, Jankowski ML, Al Khatib M, Kunt T, Lajer M, Lichtinghagen R, Lindhardt M, Maahs DM, Mischak H, Mullen W, Navis G, Noutsou M, Ortiz A, Persson F, Petrie JR, Roob JM, Rossing P, Ruggenenti P, Rychlik I, **Serra AL**, Snell-Bergeon J, Spasovski G, Stojceva-Taneva O, Trillini M, von der Leyen H, Winklhofer-Roob BM, Zürlbig P, Jankowski J.  
Nephrol Dial Transplant. 2014, 29 (8):1563-1570

IF 3.371

13. Pain identifies squamous cell carcinoma in organ transplant recipients: the SCOPE-ITSCC PAIN study. Bouwes Bavinck JN, Harwood CA, Genders RE, Wisgerhof HC, Plasmeijer EI, Mitchell L, Olasz EB, Mosel DD, Pokorney MS, **Serra AL**, Feldmeyer L, Baumann Conzett K, Piaserico S, Belloni Fortina A, Jahn K, Geusau A, Gerritsen MJ, Seckin D, Gulec AT, Cetkovska P, Ricar J, Imko-Walczuk B, Proby CM, Hofbauer GF.  
Am J Transplant. 2014, 14(3):668-76

IF 6.192

14. Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease. Spichtig D, Zhang H, Mohebbi N, Pavik I, Petzold K, Stange G, Saleh L, Edenhofer I, Segerer S, Biber J, Jaeger P, **Serra AL**, Wagner CA.  
Kidney Int. 2014, 29 (8):1563-1570

IF 7.916

15. Clinical characteristics and disease predictors of a large chinese cohort of patients with autosomal dominant polycystic kidney disease. Chen D, Ma Y, Wang X, Yu S, Li L, Dai B, Mao Z, Sun L, Xu C, Rong S, Tang M, Zhao H, Liu H, **Serra AL**, Graf N, Liu S, Wüthrich RP, Mei C.  
PLoS One. 2014 Mar 20;9(3)

IF 3.730

16. Excessive activation of the alternative complement pathway in autosomal dominant polycystic kidney disease. Su Z, Wang X, Gao X, Liu Y, Pan C, Hu H, Beyer RP, Shi M, Zhou J, Zhang J, **Serra AL**, Wüthrich RP, Mei C.  
J Intern Med. 2014, 276 (5):470-485

IF 6.455

17. Disease progress in patients with Morbus Fabry after switching from agalsidase beta to agalsidase alpha. Reidt S, Namdar M, **Serra A**, Krayenbühl PA, Gruner C, Keller DI, Lüscher TF, Schmied C.  
Intern Med J. 2014 Feb;44(2):205-7.

IF 6.455

18. The role of phospholipase D in modulating the MTOR signaling pathway in polycystic kidney disease. Liu Y, Käch A, Ziegler U, Ong AC, Wallace DP, Arcaro A, **Serra AL**.  
PLoS One. 2013 Aug 23;8(8):e73173.

IF 3.730

19. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study. Pavik I, Jaeger P, Ebner L, Wagner CA, Petzold K, Spichtig D, Poster D, Wüthrich RP, Russmann S, **Serra AL**.

Nephrol Dial Transplant. 2013 Feb;28(2):352-9.

IF 3.371

20. Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study.  
Kistler AD, **Serra AL**, Siwy J, Poster D, Krauer F, Torres VE, Mrug M, Grantham JJ, Bae KT, Bost JE, Mullen W, Wüthrich RP, Mischak H, Chapman AB.  
PLoS One. 2013;8(1):e53016.

IF 3.730

21. Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation.  
Ho TA, Godefroid N, Gruzon D, Haymann JP, Maréchal C, Wang X, **Serra A**, Pirson Y, Devuyst O.  
Kidney Int. 2012 Nov;82(10):1121-9.

IF 7.916

22. Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice.  
Terry W, Cochat P, Froissart R, Ortiz A, Pirson Y, Poppe B, **Serra A**, V Biesen W, Vanholder R, Wanner C.  
Nephrol Dial Transplant. 2013;28(3):505-17.

IF 3.371

23. Targeting of sodium-glucose co-transporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD Rats.  
Xueqi Wang X, Suhua Zhang S, Liu Y, Spichtig D, Kapoor S, Koepsell H, Mohebbi N, Segerer St, **Serra AL**, Rodriguez D, Devuyst O, Mei C, Wüthrich RP.  
Kidney Int. 2013 Nov;84(5):962-8.

IF 7.916

24. Ovarian Toxicity from Sirolimus.  
Braun M, Young J, Reiner C, Poster D, Wüthrich RP, **Serra AL**.  
N Engl J Med. 2012;366(11):1062-4.

IF 51.658

25. TUMORAPA Study Group. Sirolimus and secondary skin-cancer prevention in kidney transplantation. Euvrard S, Morelon, Lionel Rostaing, Eric Goffin E, Brocard, Tromme I, Broeders I, del Marmol V, Chatelet V, Domp Martin A, Kessler M, **Serra AL**, Hofbauer G, Pouteil-Noble C, Campistol J, Kanitakis J, Roux A, Decullier E, Dantal J.  
N Engl J Med 2012; 367:329-339.

IF 51.658

26. Low-dose oral sirolimus and the risk of menstrual-cycle disturbances and ovarian cysts: analysis of the randomized controlled SUISE ADPKD trial.  
Braun M, Young J, Reiner CS, Poster D, Krauer F, Kistler AD, Kristanto P, Wang X, Liu Y, Loffing J, Andreisek G, von Eckardstein A, Senn O, Wüthrich RP, **Serra AL**.  
PLoS One. 2012;7(10):e45868.

IF 3.730

27. Reversal of UVA Skin Photosensitivity and DNA Damage in Kidney Transplant Recipients by Replacing Azathioprine.  
Hofbauer GF, Attard NR, Harwood CA, McGregor JM, Dziunycz P, Iotzova-Weiss G, Straub G, Meyer R, Kamenisch Y, Berneburg M, French LE, Wüthrich RP, Karran P, **Serra AL**.  
Am J Transplant. 2012 Jan;12(1):218-25.

IF 6.192

28. Growth of Arachnoid Cysts in Patients with Autosomal Dominant Polycystic Kidney Disease: Serial Imaging and Clinical Relevance.  
Krauer F, Ahmadli U, Kollias S, Bleisch J, Wüthrich RP, **Serra AL**, Poster D.  
CKJ 2012.

IF 0.230

29. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study. Pavik I, Jaeger P, Ebner L, Wagner CA, Petzold K, Spichtig D, Poster D, Wüthrich RP, Russmann S, **Serra AL**.  
Nephrol Dial Transplant. 2012.

IF 3.371

30. Sirolimus induced phosphaturia is not caused by inhibition of renal apical sodium phosphate cotransporters.  
Haller M, Amatschek S, Wilflingseder J, Kainz A, Bielez B, Pavik I, **Serra A**, Mohebbi N, Biber J, Wagner CA, Oberbauer R.  
PLoS One. 2012.

IF 3.730

31. Quantitative BOLD response of the renal medulla to hyperoxic challenge at 1.5T and 3.0T.  
Donati OF, Nanz D, **Serra AL**, Boss A.  
NMR Biomed. 2012 Jan 31. doi: 10.1002.

IF 3.446

32. Soluble Klotho and Autosomal Dominant Polycystic Kidney Disease. Pavik I, Jaeger P, Ebner L, Poster D, Krauer F, Kistler AD, Rentsch K, Andreisek G, Wagner CA, Devuyst O, Wüthrich RP, Schmid C, **Serra AL**.  
Clin J Am Soc Nephrol. 2012; (2):248-57.

IF 5.068

33. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation.  
Warnock DG, Ortiz A, Mauer M, Linthorst GE, Oliveira JP, **Serra AL**, Maródi L, Mignani R, Vujkovic B, Beitner-Johnson D, Lemay R, Cole JA, Svarstad E, Waldek S, Germain DP, Wanner C; on behalf of the Fabry Registry.  
Nephrol Dial Transplant. 2012 Mar;27(3):1042-9.

IF 3.371

34. Urinary proteomic biomarkers enable diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multi-centric study.  
Kistler AD, **Serra AL**, Siwy J, Poster D, Krauer F., Torres VE, Mrug M, Grantham JJ, Bae KT, Bost JE, Mullen W, Wüthrich RP, Mischak H, Chapman AB.  
PLoS One. 2012.

IF 3.730

35. Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation. Ho TA, Godefroid N, Gruzon D, Haymann JP, Maréchal C, Wang X, **Serra A**, Pirson Y, Devuyst O.  
Kidney Int. 2012 Nov;82(10):1121-9.

IF 7.916

36. A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapy.  
Kistler AD, Siwy J, Breunig F, Jeevaratnam P, Scherl A, Mullen W, Warnock DG, Wanner C, Hughes DA, Mischak H, Wüthrich RP, **Serra AL**.  
PLoS One. 2011;6(6):e20534.

IF 3.730

37. Skin cancer development in solid organ transplant recipients: a 2 year interim analysis of the Swiss Transplant Cohort Study (STCS).  
Staubli M, Anliker M, Arnold A, Hunger R, Kempf W, Laffitte E, Lapointe AK, Mainetti C, Pelloni F, Streit M, Fehr T, **Serra A**, Hofbauer GF.  
J of Investigative Dermatology, 2011; (131): S25-S25.

IF 6.193

38. Anti-VEGF treatment accelerates polycystic kidney disease.  
Raina S, Honer M, Krämer SD, Liu Y, Wang X, Segerer S, Wüthrich RP, **Serra AL**.  
Am J Physiol Renal Physiol. 2011 Oct;301(4):F773-83.

IF 3.612

39. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangiomyomatosis: a phase 2 trial.  
Davies DM, de Vries PJ, Johnson SR, McCartney DL, Cox JA, **Serra AL**, Watson PC, Howe CJ, Doyle T, Pointon K, Cross JJ, Tattersfield AE, Kingswood JC, Sampson JR.  
Clin Cancer Res. 2011 Jun 15;17(12):4071-81.

IF 7.837

40. Renal Function in Patients Treated with Cinacalcet for Persistent Hyperparathyroidism after Kidney Transplantation.  
Henschkowski J, Bischoff-Ferrari HA, Wüthrich RP, **Serra AL**  
Kidney Blood Press Res. 2011; 34:97-103.

IF 1.596

41. Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate.  
Pavik I, Jaeger Ph., Kistler AD., Poster D., Krauer F, Cavelti-Weder C, Rentsch K, Wüthrich RP and **Serra AL**.  
Kidney Int. 2011;79(2):234-40.

IF 7.916

42. Azathioprine withdrawal results in reduction in UVA photosensitivity but persistence of potentially mutagenic DNA thiopurines.  
Attard NR, Hofbauer G, Straub G, **Serra A**, Harwood CA, McGregor J, Karran P.  
Br J of Dermatology, 2010;162:920.

IF 3.759

43. Prognostic Indicators of Renal Disease Progression in Adults with Fabry Disease: Natural History Data from the Fabry Registry.  
Wanner C, Oliveira, JP, Ortiz A, Mauer M, Germain DP, Linthorst G, **Serra AL**, Maródi L, Mignani R, Cianciaruso B, Vujkovic B, Lemay R, Beitner-Johnson D, Waldek S and Warnock DG.  
Clin J Am Soc Nephrol. 2010;5(12):2220-8.

IF 5.068

44. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.  
**Serra AL**, Poster D, Kistler AD, Krauer F, Raina S, Young J, Rentsch KM, Spanaus KS, Senn O, Kristanto P, Scheffel H, Weishaupt D, Wüthrich RP.  
N Engl J Med. 2010 Aug 26;363(9):820-9.

IF 51.658

45. Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease.  
Wu M, Arcaro A, Varga Z, Vogetseder A, Le Hir M, Wüthrich RP, **Serra AL**. Am J Physiol Renal Physiol.  
Am J Physiol Renal Physiol. 2009 Dec;297(6):F1597-605.

IF 3.612

46. Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease.  
**Serra AL**, Kistler AD, Poster D, Krauer F, Senn O, Raina S, Pavik I, Rentsch K, Regeniter A, Weishaupt D, Wüthrich RP.  
Nephrol Dial Transplant. 2009 Nov;24(11):3334-42.

IF 3.371

47. Kidney function and volume progression in unilateral ADPKD with contralateral renal agenesis or hypoplasia: a case series.  
Poster D, Kistler AD, Krauer F, Blumenfeld JD, Rennert H, Weishaupt D, Wüthrich RP and **Serra AL**.  
Am J Kidney Dis. 2009 Sep;54(3):450-8.

IF 5.294

48. Identification of a unique urinary biomarker profile in autosomal dominant polycystic kidney disease.  
Kistler AD, Mischak H, Poster D, Dakna M, Wüthrich RP and **Serra AL**.  
Kidney Int. 2009 Jul;76(1):89-96.

IF 7.916

49. Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients.  
Grimmelt A, Cohen CD, Fehr T, **Serra AL** and Wüthrich RP.  
Clin Nephrol. 2009;71(2):125-9.  
*IF 1.288*
50. Increases in kidney volume in Autosomal Dominant Polycystic Kidney Disease can be detected within 6 months.  
Kistler AD, Poster D, Krauer F, Weishaupt D, Raina S, Senn O, Binet I, Spanaus K, Wüthrich RP and **Serra AL**.  
Kidney Int. 2009 Jan;75(2):235-41.  
*IF 7.916*
51. Phosphatemic effect of cinacalcet in kidney transplant recipients with persistent hyperparathyroidism.  
**Serra AL**, Wuhrmann C, Wüthrich RP.  
Am J Kidney Dis. 2008 52(6):1151-7.  
*IF 5.294*
52. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a tuberous sclerosis patient.  
Hofbauer GFL, Marcollo-Pini A, Corsenca A, Kistler AD, French LE, Wüthrich RP, **Serra AL**.  
Br J Dermatol. 2008 Aug;159(2):473-5.  
*IF 3.759*
53. Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation.  
**Serra AL**, SC Braun, A Starke, R Savoca, M Hersberger, S Russmann, N Corti and RP Wüthrich.  
Am J Transplant. 2008 Apr;8(4):803-10.  
*IF 6.192*
54. Sirolimus ameliorates the enhanced expression of metalloproteinases in a rat model of ADPKD.  
Berthier CC, Wahl PR, Le Hir M, Marti HP, Wagner U, Rehrauer H, Wüthrich RP, **Serra AL**.  
Nephrol Dial Transplant. 2008 Mar;23(3):880-9.  
*IF 3.371*
55. Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISE ADPKD study.  
**Serra AL**, Kistler A, Poster D, Strucker M, Wüthrich RP, Weishaupt D, Tschirch F. [NCT00346918].  
BMC Nephrology 2007 Sep 15;8(1):13.  
*IF 1.644*
56. Mitotic activation of Akt signalling pathway in Han:SPRD rats with polycystic kidney disease.  
Wahl PR, Le Hir M, Vogetseder A, Arcaro A, Starke A, Waeckerle-Men Y, **Serra AL**, Wüthrich RP.  
Nephrology. 2007 Aug;12(4):357-63.  
*IF 1.688*
57. Six-year follow up of azathioprine and mycophenolate mofetil use during the first 6 months of renal transplantation.  
Rippin S, **Serra AL**, Marti HP and Wüthrich RP.  
Clin Nephrol. 2007 Jun;67(6):374-80.  
*IF 1.288*
58. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients.  
**Serra AL**, Savoca R, Huber AR, Hepp U, Delsignore A, Hersberger M, Wüthrich RP.  
Nephrol Dial Transplant. 2007 Feb;22(2):577-83.  
*IF 3.371*
59. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease.  
Wu M, Wahl PR, Le Hir M, Wackerle-Men Y, Wuthrich RP, **Serra AL**.  
Kidney Blood Press Res. 2007 Jun 27;30(4):253-259.  
*IF 1.596*

60. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).  
Wahl PR, **Serra AL**, Le Hir M, Molle KD, Hall MN, Wüthrich RP.  
Nephrol Dial Transplant. 2006 Mar;21(3):598-604.

IF 3.371

61. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism.  
**Serra AL**, Schwarz AA, Wick FH, Marti HP, Wüthrich RP.  
Nephrol Dial Transplant. 2005 Jul;20(7):1315-9.

IF 3.371

62. Sodium retention in rats with liver cirrhosis is associated with increased renal abundance of NaCl cotransporter (NCC).  
Yu Z<sup>†</sup>; **Serra A**<sup>†</sup>; Sauter D; Loffing J; Ackermann D; Frey F, Frey B; Vogt B.  
Nephrol Dial Transplant. 2005 Sep;20(9):1833-41.

IF 3.371

63. Hypoxia causes down-regulation of 11 beta-hydroxysteroid dehydrogenase type 2 by induction of Egr-1.  
Heiniger CD, Kostadinova RM, Rochat MK, **Serra A**, Ferrari P, Dick B, Frey BM, Frey FJ.  
FASEB J. 2003 May;17(8):917-9.

IF 5.704

64. Glycyrrhetic acid decreases plasma potassium concentrations in patients with anuria.  
**Serra A**, Uehlinger DE, Ferrari P, Dick B, Frey BM, Frey FJ, Vogt B.  
J Am Soc Nephrol. 2002 Jan;13(1):191-6.

IF 8.987

65. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful.  
Vogt B, Ferrari P, Schonholzer C, Marti HP, Mohaupt M, Wiederkehr M, Cereghetti C, **Serra A**, Huynh-Do U, Uehlinger D, Frey FJ.  
Am J Med. 2001 Dec 15;111(9):692-8.

IF 4.768

66. Efficiency of airway macrophage recovery by bronchoalveolar lavage in hamsters: a stereological approach.  
Geiser M, **Serra AL**, Cruz-Orive LM, Baumann M, Im Hof V, Gehr P.  
Eur Respir J. 1995 Oct;8(10):1712-8.

IF 6.355

## **B. Fallbeschreibungen (case reports)**

---

- Hydronephrosis in autosomal dominant polycystic kidney disease.  
Kistler AD, Poster D, Wüthrich RP, **Serra AL**  
Kidney Int. 2009 Dec;76(12):1297.  
IF 7.916
- Maltose cross-like crystals in the urinary sediment of a diabetic patient.  
Etter Ch, Russi R, Fogazzi GB, Wüthrich RP, **Serra AL**.  
NDT Plus 2009; 2:405-407  
IF 0.000
- Combined nephrectomy and preemptive renal transplantation in a patient with tuberous sclerosis complex.  
Corsenca A, Moch, M, Weber M, Wüthrich RP, **Serra AL**.  
Nephrol Dial Transplant. 2007 22(11):3330-3.  
IF 3.371
- A puzzling case of high serum creatinine in a healthy woman.  
**Serra AL**, Klein M, Nitsch D, Durr D, Wermuth B, Frey FJ.  
Nephrol Dial Transplant. 2006 5:1456-7.  
IF 3.371

### C. Übersichtsarbeiten (Reviews)

---

1. Looking at the (w)hole: magnet resonance imaging in polycystic kidney disease.  
Liebau MC, **Serra AL**.  
Pediatr Nephrol. 2013 Sep;28(9):1771-83.  
*IF 2.939*
2. The educational website Dermaguard to prevent the incidence of skin care after transplantation.  
Bühler MN, Feldmeyer L, Wüthrich RP, French LE, Djamei V, **Serra AL**, Hofbauer GF.  
Praxis (Bern 1994). 2013 Nov 13;102(23):1415-20.  
*IF 0.059*
3. Assessment of proteinuria.  
Nowak A, **Serra AL**.  
Praxis (Bern 1994). 2013 Jun 19;102(13):797-802.  
*IF 0.059*
4. Pre- and posttransplant management of solid organ transplant recipients: risk-adjusted follow-up.  
Schreve BS, Anliker M, Arnold AW, Kempf W, Laffitte E, Lapointe AK, Mainetti C, Pelloni F, Oberholzer P, Serra AL, Streit M, Hofbauer GF; working group Organ Transplantation, Swiss Society for Dermatology and Venerology.  
Curr Probl Dermatol. 2012;43:57-70.  
*IF 0.334*
5. Maligne Hauterkrankungen bei organtransplantierten Patienten.  
Göksu Y, Hofbauer G, Serra A, Nowak A.  
Praxis (Bern). 2012  
*IF 0.059*
6. Vasopressin-2 receptor antagonists in autosomal dominant polycystic kidney disease: from man to mouse and back.  
Devuyst O, Wang X, **Serra A**.  
Nephrol Dial Transplant. 2011 Aug;26(8):2423-5.  
*IF 3.371*
7. Swiss clinical practice guidelines for skin cancer in organ transplant recipients.  
Lapointe AK, Hofbauer G, Anliker M, Arnold A, Binet I, Hunger R, Kempf W, Pascual M, Pelloni F, **Serra A**, Laffitte E.  
Rev Med Suisse. 2010 Apr 28;6(246):854-9.  
*IF 0.121*
8. Impact of Mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.  
Wüthrich RP, Kistler AD, **Serra AL**.  
Transplant Proc. 2010 Nov;42:S44-6.  
*IF 0.952*
9. Autosomal-dominante polyzystische Nierenerkrankung: Neue therapeutische Ansätze.  
**Serra AL**, Poster D, Wüthrich RP.  
Der Nephrologe. 2010;404-411.  
*IF 0.000*
10. Neue diagnostische Aspekte bei zystischen Nierenerkrankungen.  
Kistler D, **Serra AL**.  
Der Nephrologe. 2010. 375-383.  
*IF 0.000*
11. Autosomal Dominant Polycystic Kidney Disease: New Treatment Options and How to Test Their Efficacy.  
Wüthrich RP, **Serra AL**, Kistler AD.  
Kidney Blood Press Res. 2009 Nov 3;32(5):380-387.  
*IF 1.596*



12. Mammalian target of rapamycin and autosomal dominant polycystic kidney disease.  
Wüthrich RP, **Serra AL**.  
Transplant Proc. 2009 Jul-Aug;41(6 Suppl)  
*IF 0.952*
  
13. Autosomal dominante polyzystische Nierenerkrankung (ADPKD). Pathogenese, Klinik und neue Therapieansätze.  
**Serra AL**, Wüthrich RP.  
Schweiz Med Forum 2009;9(47):854-858.  
*IF 0.000*
  
14. Autosomal dominant polycystic kidney disease (ADPKD): rapamycin as a new treatment option.  
**Serra AL**, Wüthrich RP.  
Praxis (Bern). 2009 Dec 16;98(25):1511-6.  
*IF 0.059*
  
15. mTOR Inhibitoren bremsen gutartige und bösartige vaskuläre Proliferation am Beispiel von Kaposisarkom und Angiofibrom bei tuberöser Sklerose.  
Hofbauer GFL, Marcollo-Pini A, French LE, Wüthrich RP, **Serra AL**.  
Derm. Helv. 2009; 1:17-18  
*IF 0.000*
  
16. Swiss clinical practice guidelines for skin cancer in organ transplant recipients. SGD V working group for organ transplant recipients.  
Hofbauer GF, Anliker M, Arnold A, Binet I, Hunger R, Kempf W, Laffitte E, Lapointe AC, Pascual M, Pelloni F, **Serra AL**.  
Swiss Med Wkly. 2009 Jul 25;139(29-30):407-15.  
*IF 1.821*
  
17. Polyzystische Nierenerkrankung: wenn Zysten die Niere zerstören.  
**Serra AL**, Wüthrich RP.  
Ärztliche Praxis Urologie 2008; 1:18-21  
*IF 0.000*
  
18. Use of cinacalcet to control hyperparathyroidism.  
**Serra AL**, Wüthrich RP:  
Review of endocrinology, 2008; 2:41-45.  
*IF 0.000*
  
19. Therapie des persistierenden Hyperparathyreoidismus nach Nierentransplantation.  
**Serra AL**, Wüthrich RP.  
Nephrologie im Dialog. 2007; 1:8-12.  
*IF 0.000*
  
20. Autosomal-dominante polyzystische Nierenerkrankung.  
**Serra AL**, Wüthrich RP.  
Der Nephrologe. 2007; 6:459-466  
*IF 0.000*
  
21. Wie kann die Gefässkalzifikation gestoppt werden?  
**Serra AL**, Wüthrich RP.  
CardioVasc. 2006 12-17.  
*IF 0.000*
  
22. The red urine.  
Wüthrich RP, **Serra AL**.  
Ther Umsch. 2006; 63:595-600.  
*IF 0.000*
  
23. Klassifikationen und Therapieoptionen bei chronischer Niereninsuffizienz.  
**Serra AL**, Wüthrich RP.  
CardioVasc. 2005 8-13  
*IF 0.000*

## D. Angeleitete Dissertationen

---

1. Herr Wu M. 2010. PhD an der Mathematisch-naturwissenschaftlichen Fakultät der Universität Zürich. Targeting Mammalian Target of Rapamycin (mTOR) Signaling in the Han:SPRD Rat, a Model for Polycystic Kidney Disease.
2. Frau Braun SC. 2008. MD an der Medizinische Fakultät Zürich. Der kalziumsenkende Effekt von Cinacalcet bei nierentransplantierten Patienten mit tertiärem Hyperparathyreoidismus ist durch PTH-abhängige und –unabhängige Mechanismen bedingt.
3. Herr Braun M. 2012. MD an der Medizinische Fakultät Zürich. Ovarian toxicity of Sirolimus.
4. Frau Pavik, I. 2013. PhD an der Mathematisch-naturwissenschaftlichen Fakultät der Universität Zürich. The Role and Regulation of Fibroblast Growth Hormone 23 (FGF23) in Health and Chronic Kidney Disease (CKD).
5. Frau Bühler M. 2013. MD an der Medizinischen Fakultät Zürich. Dermaguard.
6. Frau Liu Y. 2015 PhD an der Mathematisch-naturwissenschaftlichen Fakultät der Universität Zürich. Dual PI3K/mTOR inhibition prevents sirolimus induced PI3K/Akt and Ras/MAPK pathways up-regulation in polycystic kidney disease.
7. Frau Leinweber N. 2016. MD an der Medizinische Fakultät Zürich. Loss of information of skin health in kidney allograft recipients.
8. Frau Rotar L. 2017 geplante Dissertationseinreichung (PhD) an der Mathematisch-naturwissenschaftlichen Fakultät der Universität Zürich. EuroCYST-multinational academic study in ADPKD.